BNP Paribas Financial Markets
STOK icon

BNP Paribas Financial Markets’s Stoke Therapeutics STOK Stock Holding History

BNP Paribas Financial Markets’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884K Sell
27,012
-29,116
-52% -$934K ﹤0.01% 3408
2026
Q1 		$1.83M Buy
56,128
+51,871
+1,218% +$1.7M ﹤0.01% 2718
2025
Q4 		$135K Sell
4,257
-9,144
-68% -$275K ﹤0.01% 4228
2025
Q3 		$315K Buy
13,401
+9,215
+220% +$158K ﹤0.01% 3792
2025
Q2 		$47.5K Buy
4,186
+1,668
+66% +$15.8K ﹤0.01% 4278
2025
Q1 		$16.7K Sell
2,518
-1,904
-43% -$17.8K ﹤0.01% 4586
2024
Q4 		$48.8K Sell
4,422
-71,732
-94% -$881K ﹤0.01% 4443
2024
Q3 		$936K Buy
76,154
+71,647
+1,590% +$1.01M ﹤0.01% 2534
2024
Q2 		$60.9K Sell
4,507
-9,823
-69% -$133K ﹤0.01% 3403
2024
Q1 		$193K Buy
14,330
+6,636
+86% +$40.2K ﹤0.01% 3259
2023
Q4 		$40.5K Sell
7,694
-20,458
-73% -$87.4K ﹤0.01% 3599
2023
Q3 		$111K Buy
28,152
+20,847
+285% +$137K ﹤0.01% 3303
2023
Q2 		$77.7K Sell
7,305
-3,475
-32% -$37K ﹤0.01% 3346
2023
Q1 		$89.8K Sell
10,780
-20,784
-66% -$188K ﹤0.01% 3346
2022
Q4 		$291K Buy
31,564
+14,452
+84% +$150K ﹤0.01% 2848
2022
Q3 		$220K Buy
17,112
+2,736
+19% +$43.6K ﹤0.01% 3452
2022
Q2 		$190K Buy
14,376
+12,731
+774% +$193K ﹤0.01% 3110
2022
Q1 		$34.6K Sell
1,645
-2,426
-60% -$48.6K ﹤0.01% 3626
2021
Q4 		$97.7K Sell
4,071
-12,131
-75% -$289K ﹤0.01% 3602
2021
Q3 		$412K Buy
16,202
+15,492
+2,182% +$432K ﹤0.01% 2819
2021
Q2 		$23.9K Sell
710
-3,477
-83% -$123K ﹤0.01% 3486
2021
Q1 		$163K Buy
4,187
+2,235
+114% +$127K ﹤0.01% 3134
2020
Q4 		$121K Sell
1,952
-944
-33% -$43.3K ﹤0.01% 3116
2020
Q3 		$97K Buy
2,896
+2,181
+305% +$62.3K ﹤0.01% 3134
2020
Q2 		$17K Sell
715
-4,505
-86% -$107K ﹤0.01% 3472
2020
Q1 		$120K Buy
5,220
+3,958
+314% +$97.8K ﹤0.01% 3120
2019
Q4 		$35.7K Buy
1,262
+104
+9% +$2.62K ﹤0.01% 3816
2019
Q3 		$24.9K Buy
+1,158
New +$32.3K ﹤0.01% 3852

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BNP Paribas Financial Markets's STOK Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Stoke Therapeutics (STOK) stake by 52% in Q2 2026, selling an estimated $934K and leaving 27,012 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

BNP Paribas Financial Markets first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.83M in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • BNP Paribas Financial Markets held 27,012 shares of Stoke Therapeutics worth $884K as of Q2 2026.
  • BNP Paribas Financial Markets sold 29,116 Stoke Therapeutics shares in Q2 2026, an estimated $934K.
  • Stoke Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3408 holding.
  • BNP Paribas Financial Markets first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • BNP Paribas Financial Markets's Stoke Therapeutics position peaked at $1.83M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.